The Oncology & Immunology team works efficiently with partners to enable cancer drug discovery through our leading oncology and immuno-oncology capabilities. We provide a wide panel of in vivo tumor model systems including human cancer cell line-derived xenograft (CDX) models, murine syngeneic tumor models/humanized models, and patient-derived xenograft (PDX) models with in-depth genomic characterization. We have established a comprehensive immune profiling platform including TILs analysis, IHC and TCR repertoire to advance immune-oncology discovery. Our CRISPR screening can offer target validation services. The oncology & immunology team has extensive experience in IND-enabling studies for both FDA and CFDA filing, as either standalone or integrated drug discovery programs, plus clinical biomarker service to support clinical trials.
